We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
-3.33%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$9.4B
AUM Growth
-$1.47B
(-14%)
Cap. Flow
-$936M
Cap. Flow
% of AUM
-9.97%
Top 10 Holdings %
Top 10 Hldgs %
27.51%
Holding
1,295
New
171
Increased
621
Reduced
344
Closed
156
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$109M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$60M |
| 3 |
Qualcomm
QCOM
|
+$51.7M |
| 4 |
Texas Instruments
TXN
|
+$40M |
| 5 |
Microsoft
MSFT
|
+$37.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.72B |
| 2 |
Intel
INTC
|
+$70.3M |
| 3 |
KraneShares CSI China Internet ETF
KWEB
|
+$60.1M |
| 4 |
iShares China Large-Cap ETF
FXI
|
+$43.5M |
| 5 |
iShares Russell 1000 Value ETF
IWD
|
+$21.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.79% |
| 2 | Financials | 14.33% |
| 3 | Healthcare | 10.38% |
| 4 | Energy | 7.34% |
| 5 | Consumer Discretionary | 3.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
BioCryst Pharmaceuticals
BCRX
$2.28B
| $6.49M | 0.07% |
515,228
+127,901
| +33% | +$1.65M |
|
|
HZNP
252
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $6.49M | 0.07% |
104,885
+60,154
| +134% | +$4.2M |
|
253
Alkermes
ALKS
$8.22B
| $6.49M | 0.07% |
290,631
+150,117
| +107% | +$3.9M |
|
254
PTC Therapeutics
PTCT
$5.68B
| $6.48M | 0.07% |
129,158
+7,606
| +6% | +$373K |
|
255
Prothena Corp
PRTA
$425M
| $6.47M | 0.07% |
106,666
+25,194
| +31% | +$796K |
|
|
SAGE
256
DELISTED
Sage Therapeutics
SAGE
| $6.46M | 0.07% |
164,953
+67,491
| +69% | +$2.61M |
|
257
Kosmos Energy
KOS
$1.6B
| $6.46M | 0.07% |
1,249,250
-314,719
| -20% | -$1.91M |
|
258
Vanguard FTSE Europe ETF
VGK
$30.7B
| $6.44M | 0.07% |
139,632
-46,569
| -25% | -$2.43M |
|
259
Range Resources
RRC
$9.38B
| $6.44M | 0.07% |
254,991
-105,630
| -29% | -$3.19M |
|
260
SiriusXM
SIRI
$9.98B
| $6.44M | 0.07% |
112,729
+2,393
| +2% | +$150K |
|
261
Rhythm Pharmaceuticals
RYTM
$6.81B
| $6.43M | 0.07% |
+262,288
| New | +$4.88M |
|
262
Pinduoduo
PDD
$126B
| $6.41M | 0.07% |
102,485
-6,918
| -6% | -$402K |
|
263
Enphase Energy
ENPH
$4.96B
| $6.41M | 0.07% |
23,089
+3,293
| +17% | +$888K |
|
264
Baidu
BIDU
$37.7B
| $6.39M | 0.07% |
54,412
+8,251
| +18% | +$1.13M |
|
265
Lucid Motors
LCID
$2.88B
| $6.39M | 0.07% |
45,732
+3,561
| +8% | +$617K |
|
266
Denali Therapeutics
DNLI
$3.65B
| $6.36M | 0.07% |
207,368
+105,897
| +104% | +$3.44M |
|
|
CTIC
267
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $6.36M | 0.07% |
1,093,043
+655,442
| +150% | +$4.08M |
|
268
AstraZeneca
AZN
$263B
| $6.36M | 0.07% |
57,965
+5,136
| +10% | +$652K |
|
269
Charter Communications
CHTR
$17.3B
| $6.35M | 0.07% |
20,932
+6,272
| +43% | +$2.68M |
|
|
SWN
270
DELISTED
Southwestern Energy Company
SWN
| $6.35M | 0.07% |
1,036,962
-340,220
| -25% | -$2.35M |
|
|
FOLD
271
DELISTED
Amicus Therapeutics
FOLD
| $6.33M | 0.07% |
606,760
+136,451
| +29% | +$1.52M |
|
272
iShares TIPS Bond ETF
TIP
$14.6B
| $6.33M | 0.07% |
60,333
+8,090
| +15% | +$916K |
|
273
BioMarin Pharmaceuticals
BMRN
$11.6B
| $6.33M | 0.07% |
74,623
+23,802
| +47% | +$2.12M |
|
|
KRTX
274
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.26M | 0.07% |
27,826
-9,732
| -26% | -$1.97M |
|
275
iShares MSCI Emerging Markets ETF
EEM
$28.8B
| $6.24M | 0.07% |
178,979
+31,672
| +22% | +$1.24M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q3 2022 Portfolio in Review
As of Q3 2022, Rafferty Asset Management held 1,295 positions worth $9.4B, down 14% from $10.9B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Rafferty Asset Management withdrew a net $936M in Q3 2022, closing 156 positions and reducing 344 holdings. Its most notable exit was iShares Russell 1000 Value ETF, an estimated $21.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 34% a quarter earlier, followed by Financials and Healthcare.
Against the trend, Rafferty Asset Management opened a new position in American Express worth $28M.
- Rafferty Asset Management's largest Q3 2022 buy was American Express: 207,400 shares worth $28M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q3 2022, an estimated $109M increase.
- Rafferty Asset Management's biggest Q3 2022 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.72B.
- Rafferty Asset Management fully exited iShares Russell 1000 Value ETF in Q3 2022, selling an estimated $21.8M.
- Rafferty Asset Management's ten largest holdings make up 28% of its $9.4B portfolio in Q3 2022.
- Rafferty Asset Management opened 171 new positions and closed 156 in Q3 2022.
- Rafferty Asset Management's portfolio value fell 14% quarter-over-quarter to $9.4B.
Based on Rafferty Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.